Alexion, Affibody in Partnership for Autoimmune-Disease Drug
20 March 2019 - 10:16PM
Dow Jones News
By Chris Wack
Alexion Pharmaceuticals Inc. (ALXN) and Affibody AB said
Wednesday they have partnered to co-develop ABY-039 for rare
Immunoglobulin G (IgG)-mediated autoimmune diseases.
Currently in Phase 1 development, ABY-039 is a bivalent
antibody-mimetic that targets the neonatal Fc receptor. ABY-039 has
been specifically designed to combine Affibody's protein
therapeutics platform and Albumod technology to achieve a long
half-life, which, along with its small size provides the potential
for less frequent, convenient, at-home subcutaneous
administration.
Under the terms of the agreement, Alexion will provide Affibody
with an upfront payment of $25 million, with the potential for
additional development-and sales-based milestones of up to $625
million and tiered low double-digit royalty payments. Alexion will
lead joint clinical development of ABY-039 and commercialization
activities. Affibody has the option to co-promote ABY-039 in the
U.S. and will lead clinical development for an undisclosed
indication.
ABY-039 is being evaluated in a Phase 1 study in healthy
volunteers. This adaptive, double-blind, placebo-controlled study
is evaluating the safety, tolerability, pharmacokinetics and
pharmacodynamics of ABY-039 and will aid in dose selection for
future studies. The companies are assessing potential indications
for future development.
The companies expect to close the transaction in the second
quarter of 2019.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 20, 2019 07:01 ET (11:01 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Apr 2024 to May 2024
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Alexion Pharmaceuticals Inc (NASDAQ): 0 recent articles
More Alexion Pharmaceuticals, Inc. News Articles